Browsing Category

Top Industry News

7379 posts

Global Briefs: Sanofi, US Gov’t, AstraZeneca & More 
By

By
A roundup of news from Sanofi, AstraZeneca, the US Government and ADC Therapeutics. Highlights below.   * Sanofi, AstraZeneca Expand RSV Drug Production * HHS Revamps Vaccine Advisory Committee* US DOJ, FTC…

Sanofi To Acquire Blueprint Medicines in $9.5-Bn Deal
By

By
Sanofi has agreed to acquire Blueprint Medicines, a Cambridge, Massachusetts-based bio/pharmaceutical company specializing in rare diseases, in a $9.5-billion deal ($9.1 billion upfront and up to $400 million in milestone…

Zydus To Form Biologicals CDMO in $141-M Deal
By

By
Zydus Lifesiences, an Ahmedabad, India-based bio/pharmaceutical compay, has agreed to acquire the manufacturing assets of Agenus, a Lexington, Massachusetts bio/pharmaceutical company specializing in immuno-oncology, to form a new biologics CDMO…

EU Takes Next Step on Major Pharma Legislation
By

By
The Council of the European Union, composed of the ministers of the European Union’s (EU) 27 member states, took a step forward this week (June 4, 2025) on pharmaceutical policy…

FDA Launches AI Tool for Certain Agency Functions
By

By
The US Food and Drug Administration (FDA) has launched Elsa, a generative artificial intelligence (AI) tool designed to help employees—from scientific reviewers to investigators—work more efficiently.   “Following a very successful…

Novo Nordisk CEO to Step Down 
By

By
Novo Nordisk has announced that Lars Fruergaard Jørgensen, the company’s CEO, will step down from his role as CEO and will continue as CEO for a period to support a…

US Gov’t News: Latest on Tariffs & US Drug Pricing Reforms 
By

By
The latest news on US government action on tariffs and plans to implement most-favored national drug pricing in the US as part of drug-pricing reforms.   US Gov’t in Next Legal…

US Gov’t Cancels $766-M Bird Flu Vaccine Contract with Moderna 
By

By
Moderna has received notice that the US Department of Health and Human Services (HHS) will terminate its $766-million contract for the late-stage development and right to purchase the company’s avian…

Pfizer, 3SBio in $6-Bn Oncology Drug Pact 
By

By
Pfizer has entered into an exclusive global, ex-China, licensing agreement with 3SBio, a  Shenyang, China-based bio/pharmaceutical company, for the development, manufacturing, and commercialization of 3Sbio’s SSGJ-707, an investigational bispecific antibody…

Supplier News: Lonza, Bora & Shilpa Biologicals 
By

By
The latest from CDMOs, CMOs, and suppliers featuring Lonza, Bora, and Shilpa Biologicals.  Chemicals/Chemical API Manufacturing * Lonza launches API Development Platform Biologics Manufacturing * Shilpa Biologicals Opens New Bioconjugation Suite General * Bora to…